Bamlanivimab for the Prevention of Hospitalizations and Emergency Department Visits in SARS-CoV-2-Positive Patients in a Regional Health Care System
MD, MPH David H Priest, PharmD, MHA Lisa M Blanchette, MMS, PA-C Aliza L Hekman, MS Rahul Maddikunta, BSBA Paula E Burleson
Introduction: Bamlanivimab (LY-CoV555) was approved by Emergency Use Authorization by the United States Food and Drug Administration in the ambulatory setting to prevent hospitalizations and emergency department visits. We report a retrospective, case-control study of bamlanivimab use in a regional health care system. Methods: A retrospective case-control study for SARS-CoV-2-positive patients receiving bamlanivimab and matched controls between October 2020 and March 2021 was performed. End points included all-cause hospitalization, emergency department visits, and mortality. Results: No statistically significant difference was noted in all-cause hospitalization, emergency department visits, or mortality, including patients 65 years or older, body mass index of 35 or higher, diagnosis of diabetes mellitus, or cancer (high-risk patients). No difference was seen based on timing of bamlanivimab infusion relative to symptom onset or timing of infusion within the study period.
Conclusions: Based on the evaluated endpoints, there was no benefit from bamlanivimab, regardless of when it was received in a patient's clinical course or when during the study period it was received. A lack of efficacy of monoclonal antibodies in patients infected with COVID-19 variants has been noted, but the impact of local variants on these results could not be assessed given a lack of available variant diagnostic tools. These findings do not support bamlanivimab for the prevention of hospitalization or emergency department visits for patients with mild to moderate SARS-CoV-2 infection.
References
Chen, Nirula, Heller, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2029849Dhand, Lobo, Wolfe, Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: early single-center experience, Clin Transpl,
doi:10.1111/ctr.14245Focosi, Maggi, Neutralising antibody escape of SARS-CoV-2 spike protein: risk assessment for antibody-based Covid-19 therapeutics and vaccines, Rev Med Virol,
doi:10.1002/rmv.2231Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Ly-Cov555 Study Grouplundgren, Grund, Barkauskas, A neutralizing monoclonal antibody for hospitalized patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2033130Mcginley, Only one Covid-19 treatment is designed to keep people out of the hospital
Starr, Greaney, Dingens, Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016, Cell Rep Med
Tulledge-Scheitel, Bell, Larsen, A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities, J Am Geriatr Soc,
doi:10.1111/jgs.17090{ 'indexed': {'date-parts': [[2022, 1, 28]], 'date-time': '2022-01-28T06:56:24Z', 'timestamp': 1643352984074},
'reference-count': 12,
'publisher': 'Ovid Technologies (Wolters Kluwer Health)',
'issue': '2',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': ['Infect Dis Clin Pract'],
'published-print': {'date-parts': [[2022, 3]]},
'DOI': '10.1097/ipc.0000000000001130',
'type': 'journal-article',
'created': {'date-parts': [[2022, 1, 26]], 'date-time': '2022-01-26T18:00:09Z', 'timestamp': 1643220009000},
'page': '1-4',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': [ 'Bamlanivimab for the Prevention of Hospitalizations and Emergency Department Visits in '
'SARS-CoV-2–Positive Patients in a Regional Health Care System'],
'prefix': '10.1097',
'volume': '30',
'author': [ {'given': 'David H.', 'family': 'Priest', 'sequence': 'first', 'affiliation': []},
{'given': 'Lisa M.', 'family': 'Blanchette', 'sequence': 'additional', 'affiliation': []},
{'given': 'Aliza L.', 'family': 'Hekman', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rahul', 'family': 'Maddikunta', 'sequence': 'additional', 'affiliation': []},
{'given': 'Paula E.', 'family': 'Burleson', 'sequence': 'additional', 'affiliation': []}],
'member': '276',
'published-online': {'date-parts': [[2022, 1, 27]]},
'reference': [ { 'issue': '1',
'key': 'bib3-20220127',
'doi-asserted-by': 'crossref',
'first-page': '1854149',
'DOI': '10.1080/19420862.2020.1854149',
'article-title': 'Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline',
'volume': '12',
'year': '2020',
'journal-title': 'MAbs'},
{ 'key': 'bib4-20220127',
'article-title': 'Monoclonal antibodies for treating COVID-19',
'year': '2021',
'journal-title': 'Cleve Clin J Med'},
{ 'issue': '1612',
'key': 'bib5-20220127',
'first-page': '185',
'article-title': 'An EUA for bamlanivimab - a monoclonal antibody for COVID-19',
'volume': '62',
'year': '2020',
'journal-title': 'Med Lett Drugs Ther'},
{ 'issue': '3',
'key': 'bib7-20220127',
'doi-asserted-by': 'crossref',
'first-page': '229',
'DOI': '10.1056/NEJMoa2029849',
'article-title': 'SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19',
'volume': '384',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'issue': '10',
'key': 'bib8-20220127',
'doi-asserted-by': 'crossref',
'first-page': '905',
'DOI': '10.1056/NEJMoa2033130',
'article-title': 'A neutralizing monoclonal antibody for hospitalized patients with '
'Covid-19',
'volume': '384',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'issue': '7',
'key': 'bib9-20220127',
'doi-asserted-by': 'crossref',
'first-page': '632',
'DOI': '10.1001/jama.2021.0202',
'article-title': 'Effect of bamlanivimab as monotherapy or in combination with etesevimab '
'on viral load in patients with mild to moderate COVID-19: a randomized '
'clinical trial',
'volume': '325',
'year': '2021',
'journal-title': 'JAMA'},
{ 'issue': '1',
'key': 'bib12-20220127',
'doi-asserted-by': 'crossref',
'first-page': '1860476',
'DOI': '10.1080/19420862.2020.1860476',
'article-title': 'Antibodies to watch in 2021',
'volume': '13',
'year': '2021',
'journal-title': 'MAbs'},
{ 'key': 'bib13-20220127',
'first-page': 'e14245',
'article-title': 'Bamlanivimab for treatment of COVID-19 in solid organ transplant '
'recipients: early single-center experience',
'volume': '35',
'year': '2021',
'journal-title': 'Clin Transpl'},
{ 'key': 'bib14-20220127',
'doi-asserted-by': 'crossref',
'first-page': '868',
'DOI': '10.1111/jgs.17090',
'article-title': 'A mobile unit overcomes the challenges to monoclonal antibody infusion '
'for COVID-19 in skilled care facilities',
'volume': '69',
'year': '2021',
'journal-title': 'J Am Geriatr Soc'},
{ 'key': 'bib15-20220127',
'first-page': 'e2231',
'article-title': 'Neutralising antibody escape of SARS-CoV-2 spike protein: risk '
'assessment for antibody-based Covid-19 therapeutics and vaccines',
'volume': '31',
'year': '2021',
'journal-title': 'Rev Med Virol'},
{ 'issue': '4',
'key': 'bib16-20220127',
'doi-asserted-by': 'crossref',
'first-page': '100255',
'DOI': '10.1016/j.xcrm.2021.100255',
'article-title': 'Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal '
'antibody LY-CoV555 and its cocktail with LY-CoV016',
'volume': '2',
'year': '2021',
'journal-title': 'Cell Rep Med'},
{ 'issue': '1',
'key': 'bib17-20220127',
'doi-asserted-by': 'crossref',
'first-page': '1919285',
'DOI': '10.1080/19420862.2021.1919285',
'article-title': '501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab '
'in vitro',
'volume': '13',
'year': '2021',
'journal-title': 'MAbs'}],
'container-title': ['Infectious Diseases in Clinical Practice'],
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://journals.lww.com/10.1097/IPC.0000000000001130',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 1, 27]],
'date-time': '2022-01-27T09:00:22Z',
'timestamp': 1643274022000},
'score': 1,
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 1, 27]]},
'references-count': 12,
'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2022]]}},
'URL': 'http://dx.doi.org/10.1097/ipc.0000000000001130',
'relation': {},
'ISSN': ['1536-9943', '1056-9103'],
'issn-type': [{'value': '1536-9943', 'type': 'electronic'}, {'value': '1056-9103', 'type': 'print'}],
'subject': ['Infectious Diseases', 'Microbiology (medical)'],
'published': {'date-parts': [[2022, 1, 27]]}}
